Azmy, Veronica Kaman, Kelsey Tang, Daiwei Zhao, Hongyu Dela Cruz, Charles Topal, Jeffrey E. Malinis, Maricar Price, Christina C.
Published in
Journal of Clinical Immunology
We describe the cytokine profiles of a large cohort of hospitalized patients with moderate to critical COVID-19, focusing on IL-6, sIL2R, and IL-10 levels before and after receiving immune modulating therapies, namely, tocilizumab and glucocorticoids. We also discuss the possible roles of sIL2R and IL-10 as markers of ongoing immune dysregulation a...
Rajendram, Prabalini Sacha, Gretchen L. Mehkri, Omar Wang, Xiaofeng Han, Xiaozhen Vachharajani, Vidula Duggal, Abhijit
Published in
Critical Care Explorations
The primary objective was to evaluate ICU mortality at 28 days in patients with severe hypoxemic respiratory failure due to coronavirus disease 2019 infection who received tocilizumab. The secondary objectives were to evaluate ICU-, hospital-, mechanical ventilation-, and vasopressor-free days at day 28 and development of secondary infections. Desi...
Singh, Ambrish Danda, Debashish Hussain, Salman Najmi, Abul Kalam Mathew, Ashish Goel, Ruchika Lakhan, Shaheen E Tajudheen, Belzik Antony, Benny
Published in
Modern rheumatology
Takayasu arteritis (TAK) is a chronic immune vasculitis in which Interleukin-6 (IL-6) receptors play a key role in pathogenesis. Tocilizumab (TCZ), an IL-6 receptor antagonist with a favorable safety and efficacy profile, has been tried as an option for patients with TAK. This systematic review analyzed the evidence from randomized control trials (...
Hattori, Kyosuke Hirano, Yuji Kanayama, Yasuhide Hattori, Yosuke Kato, Takefumi Takahashi, Nobunori Ishiguro, Naoki Kojima, Toshihisa
Published in
Modern rheumatology
This study aimed to evaluate the efficacy of add-on iguratimod (IGU) in patients with rheumatoid arthritis (RA patients) who inadequately respond to either tocilizumab (TCZ) or tumor necrosis factor alpha inhibitors (TNFi). Twenty-three RA patients treated with TCZ (the TCZ group) and 23 RA patients treated with TNFi (the TNFi group) were enrolled ...
Hirabayashi, Yasuhiko
Published in
Modern rheumatology
To assess the efficacy of tocilizumab (TCZ) in the treatment of persistent arthritis in patients with rheumatoid arthritis (RA). The response to TCZ was evaluated in 304 patients with RA. TCZ treatment was completed after no fewer than 168 consecutive days between 28 May 2008 and 31 July 2019. Efficacy was evaluated using the DAS28-ESR and EULAR re...
Tanaka, Yoshiya Kameda, Hideto Saito, Kazuyoshi Kaneko, Yuko Tanaka, Eiichi Yasuda, Shinsuke Tamura, Naoto Fujio, Keishi Fujii, Takao Kojima, Toshihisa
...
Published in
Modern rheumatology
We evaluated long-term control of rheumatoid arthritis (RA) in Japanese paid workers (PWs) and house workers (HWs) treated with subcutaneous tocilizumab (TCZ-SC) and explored factors affecting response to TCZ-SC regarding work productivity. This study collected data from patients with RA in the TCZ-SC +/- conventional synthetic disease-modifying an...
Stredny, Coral M. Case, Siobhan Sansevere, Arnold J. Son, MaryBeth Henderson, Lauren Gorman, Mark P.
Published in
Child Neurology Open
Febrile infection-related epilepsy syndrome (FIRES) is characterized by new onset refractory status epilepticus in a previously healthy child that is associated with poor cognitive outcomes and chronic epilepsy. Innate immune system dysfunction is hypothesized to be a key etiologic contributor, with a potential role for immunotherapy blocking pro-i...
Patel, Atul Shah, Kinjal Dharsandiya, Mitkumar Patel, Ketan Patel, Tushar Patel, Mukesh Reljic, Tea Kumar, Ambuj
Published in
Indian Journal of Medical Microbiology
Background: Cytokine release storm (CRS) in severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) is thought to be the cause for organ damage and death which is independent of the actual viral burden. Tocilizumab (TCZ), an interleukin-6 receptor antagonist, is approved for the treatment of CRS. We describe the efficacy and safety of TCZ in S...
Cavalli, Giulio Farina, Nicola Campochiaro, Corrado Baldissera, Elena Dagna, Lorenzo
Published in
Expert opinion on drug safety
Adult onset Still disease (AOSD) is a rare systemic inflammatory condition. The clinical spectrum of this disease ranges from self-limiting forms with mild symptoms to life-threatening cases. Glucocorticoids and non-steroidal anti-inflammatory drugs (NSAIDs) represent the first line of therapy for AOSD, with add-on therapy with second-line drug res...
Ivan Hariyanto, Timotius Kurniawan, Andree
Published in
Journal of medical virology
Coronavirus disease 2019 (COVID-19) has caused a significant impact on all aspects of life, with the number of death cases still increasing. Therefore, identification of potential treatment for reducing the severity of the disease is important. Currently, the data regarding the effectiveness of tocilizumab as treatment agents for COVID-19 infection...